Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Cash from Financing Activities (2017 - 2020)

Monopar Therapeutics (MNPR) has disclosed Cash from Financing Activities for 4 consecutive years, with -$7140.0 as the latest value for Q4 2020.

  • Quarterly Cash from Financing Activities fell 100.08% to -$7140.0 in Q4 2020 from the year-ago period, while the trailing twelve-month figure was $8.2 million through Dec 2020, down 12.47% year-over-year, with the annual reading at $91.6 million for FY2025, 54.45% up from the prior year.
  • Cash from Financing Activities hit -$7140.0 in Q4 2020 for Monopar Therapeutics, down from $6.7 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $9.4 million in Q4 2019 to a low of -$206270.0 in Q4 2018.
  • Historically, Cash from Financing Activities has averaged $2.1 million across 4 years, with a median of $508044.0 in 2020.
  • Biggest five-year swings in Cash from Financing Activities: crashed 2162.49% in 2018 and later skyrocketed 50810.13% in 2020.
  • Year by year, Cash from Financing Activities stood at $10001.0 in 2017, then plummeted by 2162.49% to -$206270.0 in 2018, then surged by 4650.77% to $9.4 million in 2019, then plummeted by 100.08% to -$7140.0 in 2020.
  • Business Quant data shows Cash from Financing Activities for MNPR at -$7140.0 in Q4 2020, $6.7 million in Q3 2020, and $946404.0 in Q2 2020.